Agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-15. Numbers and descriptions here follow the published literature rather than marketing material.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
| Property | Value | Notes |
|---|---|---|
| Solubility class | Freely soluble in water | Also soluble in DMSO and some alcohols |
| Typical storage temperature | -20 C or below | Desiccated, protected from light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
| Typical reported purity | 95 percent or higher | Reference-grade material |
| Common synonyms | PT-141 | Also called bremelanotide acetate |
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
=== CNO-II === In a minor branch of the above reaction, occurring in the Sun's core 0.04% of the time, the final reaction involving 157N shown above does not produce carbon-12 and an alpha particle, but instead produces oxygen-16 and a photon and continues
==== Dopamine precursors and related ==== Carbidopa (Lodosyn) – aromatic L-amino acid decarboxylase (AAAD) inhibitor Carbidopa/levodopa (Crexont; IPX-203; IPX203) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [324] Foscarbidopa/foslevodopa (ABBV-951; foslevodopa/foscarbidopa; levodopa/carbidopa prodrug; Produodopa; Vyalev) – combination of foscarbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and foslevodopa (dopamine precursor) [325] Levodopa (CVT-301; CXG-89; Inbrija) – dopamine precursor and indirect non-selective dopamine receptor agonist [326] Levodopa/benserazide (co-beneldopa) (Madopar, Prolopa) – combination of levodopa (dopamine precursor) and benserazide (aromatic L-amino acid decarboxylase (AAAD) inhibitor) Levodopa/carbidopa extended-release (GSK-587124; IPX-066; Numient; Patrome; Rytary) – combination of levodopa (dopamine precursor) and carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) [327] Levodopa/carbidopa intraduodenal (ABT-SLV187; carbidopa/levodopa enteral suspension; Duodopa; Duopa; LCIG; levodopa/carbidopa intestinal gel) – combination of levodopa (dopamine precursor) and carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) [328] Melevodopa/carbidopa (carbidopa/melevodopa; CHF-1512; CNP-1512; GT-1512; levodopa methyl ester/carbidopa; Sirio; V-1512) – combination of melevodopa (dopamine precursor) and carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) [329]
== Indications == DBNPA is used as a disinfectant, bactericide, algicide, slime remover, and mildew inhibitor in several industrial applications. It is frequently used to regulate the growth of bacteria, algae, and slime in oilfield water injection systems and circulating cooling water systems. DBNPA is used in the paper industry as a slime remover, bactericide, and algicide to keep machinery free of microorganisms and maintain product quality. Additionally, it is utilized as a preservative to prevent microbiological deterioration in paints, waxes, inks, detergents, surfactants, slurries, and resins. DBNPA also serves as a fungicide and algaecide in municipal water landscapes, guaranteeing water safety and clarity, and as a biocide in process water and air purifier systems in the machinery manufacturing sector. The concentration used when it is being used as a water treatment slime stripper is 30~50 mg/L. When it is being used for water treatment, as a bactericide, it is used at a concentration of 10~20 mg/L. In terms of analytical detection in industrial and environmental samples, high-performance liquid chromatography with UV detection, measuring absorption at 230 nm, detects DBNPA at extremely low concentrations (>0.1 mg/L) in water samples. Gas chromatography-mass spectrometry can also identify and quantify DBNPA and the associated degradation products, (detection limit is 0.05 mg/L) in environmental samples.
Sources: en.wikipedia.org
== History == AryoGen Pharmed is the first and largest mAb producer in MENA region with the vision of manufacturing high-quality biosimilar products for patients suffering from life-threatening diseases around the world and improving patient’s quality of life. AryoGen pharmed produces its own Active Pharmaceutical Ingredients (APIs) Using large-scale bioreactors according to cGMP guidelines, which have been approved by PIC/s members. Research and Development unit with laboratory-scale and pilot-scale production lines is equipped with cell culture equipment such as bioreactors and recombinant protein purification Facility. The state-of-the-art manufacturing sites of AryoGen have received major accreditation such as EU GMP European Medicines Agency (EMA). The quality of all products have been certified by the most reputable laboratories around the world. AryoGen Pharmed has several Tech-Transfer projects in different countries such as Turkey, Russia and Tunisia. In addition, the products of AryoGen Pharmed have been exported to different countries in Asia, Africa and Latin America.
== Structure == The edited sites are found within the insulin growth factor binding domain of IGFBP7 and also Heparin binding domain. This region is also a site for proteolytic cleavage. Structural analysis of the edited sites determined that the two amino acids that corresponded to the edited sites are not directly involved in binding to IGF-1 but are found in regions flanking them. At position 78 in unedited version of the transcript there is an Arginine close to residue valine-49. This Valine is important in hydrophobic interaction of Phenylalanine of IGF-1. A substitution to a Glycine at this position is thought to introduce additional flexibility leading to a change of loop conformation, thereby disrupting the hydrophobic interaction that stabilises the complex. At amino acid position 98 the unedited transcript contains a lysine. This residue makes some non specific interactions via the aliphatic part of the side chain with Glu-38 of IGF-1. In the edited version the position is an arginine. The long side chain of which is thought to be able to maintain these weak interactions.
== Diagnosis == Diagnosis of the onset of HD can be made following the appearance of physical symptoms specific to the disease. Genetic testing can be used to confirm a physical diagnosis if no family history of HD exists. Even before the onset of symptoms, genetic testing can confirm if an individual or embryo carries an expanded copy of the trinucleotide repeat (CAG) in the HTT gene that causes the disease. Genetic counseling is available to provide advice and guidance throughout the testing procedure and on the implications of a confirmed diagnosis. These implications include the impact on an individual's psychology, career, family-planning decisions, relatives, and relationships. As of 2007 one study showed that despite the availability of pre-symptomatic testing, only 5% of those at risk of inheriting HD choose to do so.
== Prognosis == Long-term outcomes for people with sCSFLS remain poorly studied. Symptoms may resolve in as little as two weeks as the dura mater lining heals naturally, or they can persist for months. Less commonly, patients may have unremitting symptoms for many years. People with chronic sCSFLS may be disabled and unable to work. Recurrent CSF leak at an alternate site after recent repair is common.
Sources: en.wikipedia.org
== Treatment == In May 2023, the US Food and Drug Administration (FDA) approved Vyjuvek for the treatment of wounds in people with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
Despite this policy, in May 1972 it issued the Alice Declaration, in which it called for students to boycott lectures in response to the expulsion of SASO member Abram Onkgopotse Tiro from the University of the North after he made a speech criticising its administration. The Tiro incident convinced the government that SASO was a threat. In Durban, Biko entered a relationship with a nurse, Nontsikelelo "Ntsiki" Mashalaba; they married at the King William's Town magistrates court in December 1970. Their first child, Nkosinathi, was born in 1971. Biko initially did well in his university studies, but his grades declined as he devoted increasing time to political activism. Six years after starting his degree, he found himself repeating his third year. In 1972, as a result of his poor academic performance, the University of Natal barred him from further study.
Plasmids with specially-constructed features are commonly used in laboratory for cloning purposes. These plasmid are generally non-conjugative but may have many more features, notably a "multiple cloning site" where multiple restriction enzyme cleavage sites allow for the insertion of a transgene insert. The bacteria containing the plasmids can generate millions of copies of the vector within the bacteria in hours, and the amplified vectors can be extracted from the bacteria for further manipulation. Plasmids may be used specifically as transcription vectors and such plasmids may lack crucial sequences for protein expression. Plasmids used for protein expression, called expression vectors, would include elements for translation of protein, such as a ribosome binding site, start and stop codons.
Sources: en.wikipedia.org
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.
Aqueous solutions are subject to oxidation and hydrolysis, so concentration and pH drift can occur even under refrigeration. Solid, dry material held cold and desiccated degrades far more slowly.
Mass spectrometry separates the parent from analogues that differ by a single modification, such as an amide versus acid terminus. Retention time alone is less reliable because closely related peptides can co-elute.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.